Company intelligence / Profile preview

NEXEL Co., Ltd.

Seoul, South Koreanexelshelvingusa.com ↗

Ownership: Private
Development stage: Other

Overview

NEXEL has commercialized functional cell models derived from human induced pluripotent stem cells (hiPSCs), including both 2D monolayers and 3D organoids. These are used primarily for drug screening and evaluation in the pharmaceutical development process. The company positions itself as a leader in iPSC-based products in Korea and seeks collaborations to develop New Approach Methodologies (NAMs) for drug discovery.

Therapeutic areas: Other
Modalities: iPSC-derived cells (induced pluripotent stem cell technology)2D monolayers3D organoids
Industry: Non-Drug Biotech

Partnerships

Open to collaborations with pharma/biotech companies for NAMs development using their hiPSC-based technologies

Beyond the preview

Go deeper on NEXEL Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEXEL Co., Ltd..

Explore the full profile